Part VI: Summary of the risk management plan

Summary of risk management plan for ADEFOCIN (ampicillin)

This is a summary of the risk management plan (RMP) for ADEFOCIN. The RMP details important risks of ADEFOCIN and how more information will be obtained about ADEFOCIN's risks and uncertainties (missing information).
ADEFOCIN's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how ADEFOCIN should be used.

Important new concerns or changes to the current ones will be included in updates of ADEFOCIN's RMP.

I. The medicine and what it is used for

ADEFOCIN is authorised to treat the following diseases: Acute exacerbation of chronic bronchitis (infections of the airways), Pyelonephritis (upper urinary tract infection), Bacterial meningitis (infection of the membranes covering the brain), Pneumonia (infection of the lungs) when another penicillin does not help or is inappropriate for other reasons, Intra-abdominal infections (infection of the stomach and gut), Bacterial infection of the blood associated with any of the infections mentioned above. ADEFOCIN is also used for the treatment and prevention of endocarditis (infection of the heart valves). It contains ampicillin as the active substance and it is given by injection, parenteral administration.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of ADEFOCIN, together with measures to minimise such risks and the proposed studies for learning more about ADEFOCIN risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute ***routine risk minimisation*** **measures**.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute ***routine pharmacovigilance activities***.

II.A List of important risks and missing information

Important risks of ADEFOCIN are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of ADEFOCIN. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g., on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of ADEFOCIN.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for ADEFOCIN.